ClinConnect ClinConnect Logo
Search / Trial NCT05271578

MRI and Biological Markers of Acute E-Cigarette Exposure in Smokers and Vapers

Launched by UNIVERSITY OF PENNSYLVANIA · Mar 8, 2022

Trial Information

Current as of November 08, 2025

Recruiting

Keywords

Magnetic Resonance Imaging Electronic Cigarettes Endothelial Dysfunction Nicotine Inflammation

ClinConnect Summary

This clinical trial is studying how using electronic cigarettes (e-cigarettes) and traditional tobacco cigarettes affects blood flow and inflammation in the body. Researchers want to see what happens to smokers and vapers when they are exposed to e-cigarettes with or without nicotine, compared to non-smokers. Participants will undergo three different exposure sessions, where they will have MRI scans (a type of imaging that looks at blood flow) and blood tests done before and after using the products. The information gathered will help understand the impact of these substances on health.

To participate, individuals aged 18 to 45 who have been regular users of e-cigarettes or tobacco for at least six months may be eligible. However, those with certain health conditions such as cancer, serious heart or lung diseases, or those taking specific medications may not qualify. Participants can expect to visit the research site for multiple sessions to complete the MRI scans and blood draws. It’s important for potential participants to know that their health and safety are a top priority, and anyone interested should discuss their eligibility with the study team.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • BMI: 18.5 to 30
  • Current users of electronic cigarettes or tobacco cigarettes with a use history of six months or greater.
  • Exclusion Criteria:
  • Cancer
  • HIV
  • Mental illness in which the participant is not of proper cognizance
  • Overt cardio- or neurovascular disease (prior heart attack, stroke, transient ischemic attacks)
  • Serious arrhythmias
  • Bronchospastic disease
  • Upper respiratory tract infection within the past six weeks
  • Medication affecting vascular function
  • Antibiotics
  • Magnetic resonance imaging contraindications (metallic implants/intraocular foreign bodies, claustrophobia, cardiac/cochlear implantable electronic devices, etc.)

About University Of Pennsylvania

The University of Pennsylvania, a prestigious Ivy League institution located in Philadelphia, is renowned for its commitment to advancing medical research and improving healthcare outcomes. As a clinical trial sponsor, the university leverages its extensive resources, interdisciplinary expertise, and cutting-edge facilities to conduct innovative studies across various therapeutic areas. With a focus on translating scientific discoveries into clinical applications, the University of Pennsylvania fosters collaborations among leading researchers, clinicians, and industry partners, ensuring rigorous trial design and adherence to ethical standards. Through its dedication to excellence in research and education, the university plays a pivotal role in shaping the future of medicine.

Locations

Philadelphia, Pennsylvania, United States

Patients applied

0 patients applied

Trial Officials

Felix W Wehrli, PhD

Principal Investigator

University of Pennsylvania

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials